Fly News Breaks for November 5, 2019
Nov 5, 2019 | 16:05 EDT
Chardan analyst Geulah Livshits initiated coverage of Rocket Pharmaceuticals with a Buy rating and $30 price target citing the potential of its blended ex vivo/in vivo gene therapy pipeline. The analyst said Rocket is rapidly advancing its pipeline with 4 company sponsored INDs cleared within the last 12 months to provide transformative treatments for patients with rare monogenic diseases and shareholder value through inflection points.
News For RCKT From the Last 2 Days